Clinical case of long-term use of durvalumab in the treatment of advanced small-cell lung cancer

Cover Page

Abstract


Over the last few decades there was a little progress in the treatment of small cell lung cancer (SCLC). But now the approaches are changing with immune checkpoint inhibitors coming into clinical practice. Using a combination of immunotherapy with the standard chemotherapy in the first line of extensive stage small cell lung cancer (ES-SCLC) results in significant overall survival improvement, for the first time the median survival in these patients exceeded one year. Here we present a clinical case of ES-SCLC patient treated with durvalumab, a monoclonal antibody against PD-L1, in combination with etoposide and carboplatin in the CASPIAN clinical trial. In the CASPIAN trial more than 20% of patients treated with durvalumab stay alive more than two years. In the presented case we also reported durable control of the disease, the patient continued to receive durvalumab of more than two years with acceptable tolerability.


Full Text

Restricted Access

About the authors

Galina B. Statsenko

Omsk Regional Clinical Oncology Dispensary

Author for correspondence.
Email: galina.stacenko.00@mail.ru
ORCID iD: 0000-0001-7123-8639

Russian Federation, Omsk

deputy chief physician

Vyacheslav I. Kurakin

Omsk Regional Clinical Oncology Dispensary

Email: KurakinVI@mail.ru
ORCID iD: 0000-0002-6580-9607

Russian Federation, Omsk

Chief of Chemotherapy Department №1

Irina V. Plokhotenko

Omsk Regional Clinical Oncology Dispensary

Email: plokirina@yandex.ru
ORCID iD: 0000-0002-1257-1586

Russian Federation, Omsk

thoracic oncologist of the polyclinic

References

  1. SEER Cancer Statistics Review (1975-2016, National Cancer Institute. Bethesda, MD). Eds. N Howlander et al. https://seer.cancer.gov/csr/1975_2016/.
  2. Barta JA et al. Global Epidemiology of Lung Cancer. Annals of Global Health 2019; 85 (1): 8, 1–16.
  3. Состояние онкологической помощи населению России в 2018 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. [The status of cancer care for the population of Russia in 2018. Pod red. A.D. Kaprina, V.V. Starinskogo, G.V. Petrovoi. Moscow: MNIOI im. P.A. Gertsena – filial FGBU «NMITs radiologii’ Minzdrava Rossii, 2019 (in Russian).]
  4. Bernhardt EB, Jalal SI. Small Cell Lung Cancer. Cancer Treat Res 2016; 170: 301–22.
  5. Lampaki S et al. Small Cell Lung Cancer: Current and Future Strategies. Oncomedicine 2016; 1: 4–13.
  6. Koinis F et al. Small cell lung cancer (SCLC): no treatment advances in recent years. Transl Lung Cancer Res 2016; 5: 39–50.
  7. Чубенко В.А., Бычков М.Б., Деньгина Н.В. и др. Практические рекомендации по лекарcтвенному лечению мелкоклеточного рака легкого. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2 2019; 9: 49–54. [Chubenko V.A., Bychkov M.B., Den’gina N.V. et al. Prakticheskie rekomendatsii po lekarctvennomu lecheniiu melkokletochnogo raka legkogo. Zlokachestvennye opukholi: Prakticheskie rekomendatsii RUSSCO #3s2 2019; 9: 49–54. (in Russian).]
  8. Ready N et al. Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. J Thorac Oncol 2019; 14 (2): 237–44.
  9. Chung H et al. Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. J Thorac Oncol 2020; 15 (4): 618–27.
  10. Paz-Ares L et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 2019; 394 (10212): 1929–39.
  11. Paz-Ares L et al. Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated Results from the phase III CASPIAN study. J Clin Oncol 2020; 38 (Suppl.): abstr 9002.
  12. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Small Cell Lung Cancer. Version 3.2020. February 5, 2020.
  13. Paz-Ares L et al. PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: results from CASPIAN. Ann Oncol 2019; 30 (Suppl. 5): v851-v934. 10.1093/annonc/mdz394
  14. Chen Y et el. First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes. J Clin Oncol 2020; 38 (Suppl.): abstr 9068.

Supplementary files

Supplementary Files Action
1.
Fig. 1. The patient, born 1934. MSCT of the chest cavity with contrast, September 2017 (before the treatment).

Download (181KB) Indexing metadata
2.
Fig. 2. The patient, born 1934. MSCT of the chest cavity with contrast, November 2019 (two years after the beginning of the therapy).

Download (159KB) Indexing metadata
3.
Fig. 3. The patient, born 1934. MSCT of the chest cavity, January 2020 (after the end of durvalumab therapy).

Download (142KB) Indexing metadata
4.
Fig. 4. The patient, born 1934. MSCT of the chest cavity, April 2020 (after 4 courses of PCT using RB scheme).

Download (160KB) Indexing metadata

Statistics

Views

Abstract - 26

PDF (Russian) - 0

Cited-By


PlumX

Dimensions

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies